We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

By LabMedica International staff writers
Posted on 19 Feb 2026

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. More...

Predicting who will benefit from treatment remains challenging, especially because tumors interact dynamically with their surrounding microenvironment. Existing computational tools typically focus on cell composition but overlook gene expression changes relative to the tumor’s unique biological context. Researchers have now developed a new computational biomarker that more accurately predicts chemotherapy response and identifies patients who may benefit from alternative therapies.

Researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) have developed a novel integrative analysis approach incorporating tumor-specific total mRNA expression, known as the TmS biomarker. The method builds on deconvolution strategies by accounting for the ratio of tumor to non-tumor cells and adjusting for chromosomal abnormalities in cancer cells. By integrating gene expression data with microenvironment context, the tool captures cancer-specific biological mechanisms often missed by traditional models.

In a dataset of 575 patients with triple-negative breast cancer across diverse ethnic cohorts, the TmS biomarker successfully stratified patients into high-TmS groups with a favorable prognosis and low-TmS groups with poorer outcomes. The study, published in Cell Reports Medicine, showed that TmS outperformed existing computational methods in predicting chemotherapy response. The analysis also revealed population-specific differences between Western and Asian tumors, offering insights into tailored treatment strategies.

The TmS biomarker may serve as an effective starting point for patient stratification, guiding chemotherapy decisions and identifying candidates for alternative therapies. Its ability to capture microenvironment-driven gene expression changes positions it as a promising tool for precision oncology. Although further clinical validation is required, researchers believe the approach could improve treatment optimization across diverse populations and advance data-driven decision-making in breast cancer care.

“Deconvolution strategies are not one size fits all,” said Professor Wenyi Wang, PhD, senior author of the study. “We’re focused on making these methods more accessible to researchers without extensive computational backgrounds, with the goal of translating these powerful analytical approaches into practical tools that the broader cancer research community can readily apply to advance precision medicine.”

Related Links:
MD Anderson Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Onvaro’s commercial portfolio will be anchored by the binx io platform, an FDA-cleared, CLIA-waived molecular point-of-care system with more than 1,000 installed instruments. (Photo courtesy of binx health)

New Diagnostics Company Onvaro Formed to Expand Decentralized Testing

Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.